Categories

10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Please note

Note: The artciles are not research reports but assimilation of information available on public domain and it should not be treated as a research report.

Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”

Disclosure: It is safe to assume that I might have the dkiscussed companies in my portfolio and hence my point of view can be biased.Readers should consult registered consultants before making any investments
.

Archives : Old artciles

Wednesday, May 20, 2009

Anu's Laboratories Ltd:-Future outlook and growth prospects

Scripscan:Anu's Laboratories Ltd
cmp:50
Traded in:bse

Story:Incorporated in 1996, Anu''s Labs is a pharma company involved in basic and advanced intermediates, APIs and fine chemicals. The company is also involved in contract manufacturing of intermediates, which are purchased by bulk drug manufacturers for further processing. The company''s top five products together contribute 96% to its total revenues. Anu''s Labs is the market leader in most of these products, commanding 60-70% market share. The company has an in-house research and development division, concentrated on structured process chemistry. In the domestic market, Dr Reddy''s Labs is Anu''s Labs'' largest customer, contributing 47% to its total revenues. Hiran Orgochem, Sun Pharma, Sreepathi Pharma and Matrix Labs are its other major customers. Exports constitute nearly 20% of the company''s business, with Israel-based Teva, the world''s largest generic player, being its largest overseas customer. Sales to Teva comprise 12.5% of Anu''s Labs'' total turnover. ABIC, Polpharma and Sanofi Aventis are other major overseas buyers of the company''s products.Anu''s Labs intends to expand its manufacturing capacity by 200 tonnes. It is also setting up a pilot plant to explore opportunities in the contract research and manufacturing services (CRAMS) sector.Two years ago, Anu''s Labs, along with its promoters, had bought nearly 50% in loss-making Nitya Laboratories, to turn it around. However, Nitya, which manufactures bulk drugs and intermediates, is still a sick company. Further, given the nature of its work, Anu''s Labs may face a conflict of interest with Nitya.At the given size and growth, Anu''s Labs'' P/E is slightly higher than that of its peers including SMS Pharma and Neuland Labs.While the company''s PBDIT margin is similar to that of other pharma companies, its return on capital employed (RoCE), at 49, is substantially higher compared to its peers, which have RoCE between 15 and 25. High product and client concentration is one of its main concerns. Moreover, it faces stiff competition from Chinese imports. This forces the company to focus on being cost-competitive. But investors with high risk appetite can consider the scrip at dips as the company operates in a growth-oriented business in the defensive pharma sector.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
 
x

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner